Standout Papers

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma... 2015 2026 2018 2022 322
  1. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial (2015)
    Jean‐Charles Soria, Enriqueta Felip et al. The Lancet Oncology
  2. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer (2019)
    Mary L. Disis, Matthew H. Taylor et al. JAMA Oncology

Immediate Impact

11 from Science/Nature 67 standout
Sub-graph 1 of 19

Citing Papers

Ultrasound-Based Micro-/Nanosystems for Biomedical Applications
2024 Standout
Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
5 intermediate papers

Works of Vikram K. Chand being referenced

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
2015 Standout
Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations
2014
and 1 more

Author Peers

Author Last Decade Papers Cites
Vikram K. Chand 1168 969 52 381 64 1.7k
Giovanni Fucà 1089 530 365 86 1.7k
Andrew Dean 1016 665 248 100 1.5k
Christian Rothermundt 999 949 746 78 2.2k
Georgy M. Manikhas 1392 1064 593 35 1.9k
Jane Robertson 1263 500 807 56 2.0k
Coraline Dubot 821 349 222 59 1.3k
Tarek Meniawy 1170 553 619 92 2.0k
Jean‐François Martini 1072 1204 748 56 1.9k
Holger W. Hirte 969 426 758 44 2.0k
Catherine A. Shu 1002 982 255 61 1.5k

All Works

Loading papers...

Rankless by CCL
2026